Health In Tech Receives Two Nasdaq Deficiency Letters: Audit Committee Composition and Sub-$1.00 Bid Price
HIT is trading near its 52-week low of $0.614 (6.2% above the low) on light trading volume (0.1× avg).
Summary
Health In Tech received two Nasdaq deficiency letters — one for falling below the independent director and audit committee requirements after a board resignation, and one for a sub-$1.00 bid price over 30 days. Both have cure periods, but a reverse stock split is now explicitly under consideration.
Key Events · Legal and Risk Events · HIT
-
Two Nasdaq Deficiency Letters Disclosed
Nasdaq letters dated October 12 and October 14, 2026 flag a bid price deficiency and an independent director/audit committee deficiency. Neither has immediate effect on listing or trading.
-
Audit Committee Falls Below Three Members
After Sanjay Shrestha's August 10, 2026 resignation, the board is four directors with only two independent (William D. Howard, Timoty Hayes), and the audit committee has two members against Nasdaq's three-member minimum.
-
Bid Price Below $1.00 for 30 Days
The Class A stock closed under $1.00 for 30 consecutive business days, breaching Nasdaq Rule 5550(a)(2). The company has until April 12, 2027 to regain compliance, with a possible additional 180-day period.
-
Reverse Split Explicitly on the Table
The company says it may effect a reverse stock split to cure the bid price deficiency, which would have to be completed at least 10 business days before April 12, 2027.
Analysis · HIT · Finance
Health In Tech disclosed two separate Nasdaq Staff letters. The first, dated October 14, 2026, states that the company no longer meets Nasdaq's independent director and audit committee rules because Sanjay Shrestha resigned from the board and audit committee on August 10, 2026 — a resignation already reported in the August 13 10-Q, but the resulting Nasdaq deficiency letter is new. The board now has four directors, only two of whom are independent (William D. Howard and Timoty Hayes), and the audit committee has just two members against a three-member minimum. The second letter, dated October 12, 2026, notes that the Class A stock closed below $1.00 for 30 straight business days, breaching Nasdaq's minimum bid price rule. Neither letter immediately affects listing or trading, and the company has cure windows — until the earlier of the next annual meeting or August 10, 2027 for the committee issue, and until April 12, 2027 for the bid price. The company says it expects to fix the committee issue by electing a new independent director at the November 10, 2026 annual meeting, and it may use a reverse stock split to fix the bid price. The stakes: two simultaneous listing deficiencies on a stock already trading at $0.65, with a November 10 proxy vote pending on tripling authorized shares to 720 million and expanding the Yorkville standby equity program. A reverse split is now explicitly on the table as a compliance tool, which would interact with that share-count vote.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HIT was trading at $0.65 on NASDAQ in the Finance sector, with a market capitalization of approximately $42.6M. The 52-week trading range was $0.61 to $3.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.